Iradimed (NASDAQ:IRMD – Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Iradimed to post earnings of $0.35 per share for the quarter. Iradimed has set its FY 2024 guidance at 1.520-1.620 EPS and its Q3 2024 guidance at 0.380-0.410 EPS.
Iradimed (NASDAQ:IRMD – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $0.38 EPS for the quarter, beating the consensus estimate of $0.33 by $0.05. The firm had revenue of $17.93 million during the quarter, compared to the consensus estimate of $17.70 million. Iradimed had a return on equity of 24.71% and a net margin of 26.83%. During the same period in the prior year, the business earned $0.33 EPS. On average, analysts expect Iradimed to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Iradimed Stock Up 0.0 %
IRMD opened at $50.51 on Friday. The business has a 50 day moving average price of $48.24 and a two-hundred day moving average price of $45.14. The company has a market cap of $639.66 million, a PE ratio of 35.82 and a beta of 0.79. Iradimed has a 52 week low of $38.67 and a 52 week high of $52.45.
Iradimed Announces Dividend
Analyst Ratings Changes
Separately, Roth Mkm cut their target price on Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, August 2nd.
Check Out Our Latest Analysis on IRMD
Iradimed Company Profile
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Read More
- Five stocks we like better than Iradimed
- What is the Hang Seng index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Earnings Per Share Calculator: How to Calculate EPS
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.